{"preliminary_commentary":{"by_channel":{"x_thread":11,"podcast":3,"youtube":1},"note":"Preliminary. Indexed podcasts, YouTube videos and posts on X and Bluesky that name this trial so far. LinkedIn posts are read for reports and the Enterprise MCP, not yet for this index. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT05085028\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["pembrolizumab"]],"indication":"first-line advanced non-small cell lung cancer","name":"REFINE-Lung","nct_id":"NCT05085028","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=refine-lung-nct05085028. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":"REFINE-Lung","arms":[{"description":"6 weekly pembrolizumab, 400mg intravenous","label":"6 weekly","type":"ACTIVE_COMPARATOR"},{"description":"9 weekly pembrolizumab, 400mg intravenous","label":"9 weekly","type":"EXPERIMENTAL"},{"description":"12 weekly pembrolizumab, 400mg intravenous","label":"12 weekly","type":"EXPERIMENTAL"},{"description":"15 weekly pembrolizumab, 400mg intravenous","label":"15 weekly","type":"EXPERIMENTAL"},{"description":"18 weekly pembrolizumab, 400mg intravenous","label":"18 weekly","type":"EXPERIMENTAL"}],"collaborators":["National Institute for Health Research, United Kingdom","Medical Research Council","University College, London"],"completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"conditions":["Lung Cancer, Nonsmall Cell"],"enrollment":{"count":1750,"type":"ESTIMATED"},"has_results":false,"interventions":[{"name":"Pembrolizumab 25 MG/ML [Keytruda]","otherNames":[],"type":"DRUG"}],"last_update":"2024-03-07","lead_sponsor":"Imperial College London","official_title":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Utilising a Novel Multi-arm Frequency-response Optimisation Design","overall_status":"RECRUITING","phases":["PHASE3"],"primary_completion_date":{"date":"2027-05-31","type":"ESTIMATED"},"primary_outcomes":[{"measure":"Overall survival at 2 years","timeFrame":"18 months from randomisation"}],"references":[{"citation":"Ghorani E, Quartagno M, Blackhall F, Gilbert DC, O'Brien M, Ottensmeier C, Pizzo E, Spicer J, Williams A, Badman P, Parmar MKB, Seckl MJ; REFINE-Lung Investigators. REFINE-Lung implements a novel multi-arm randomised trial design to address possible immunotherapy overtreatment. Lancet Oncol. 2023 May;24(5):e219-e227. doi: 10.1016/S1470-2045(23)00095-5.","pmid":"37142383","type":"DERIVED"}],"start_date":{"date":"2022-06-23","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)","url":"https://clinicaltrials.gov/study/NCT05085028"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.3","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/refine-lung-nct05085028"}